Showing results (201-210 of 211) with videos related to

Sort By:
Pageof 22
Blood Cancer Journal|March 15, 2018
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasmsValerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro, et al.
Cancer|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world studyFrancesca Palandri, Monia Marchetti, Elena M Elli, et al.
Leukemia|May 31, 2019
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control studyTiziano Barbui, Arianna Ghirardi, Arianna Masciulli, et al.
Hematological Oncology|May 9, 2025
Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient PopulationMassimo Breccia, Antonella Russo Rossi, Valentina Giai, et al.
American Journal of Hematology|December 10, 2019
Second cancers in MPN: Survival analysis from an international studyMonia Marchetti, Arianna Ghirardi, Arianna Masciulli, et al.
British Journal of Haematology|October 12, 2021
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML reportMassimo Breccia, Elisabetta Abruzzese, Vincenzo Accurso, et al.
Oncotarget|September 1, 2016
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Alessandro Nobili, Roberto Latagliata, et al.
Blood|December 27, 2019
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML studySimona Soverini, Luana Bavaro, Caterina De Benedittis, et al.
Leukemia|January 8, 2021
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinibTiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, et al.
Blood Cancer Journal|February 10, 2021
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19Tiziano Barbui, Valerio De Stefano, Alberto Alvarez-Larran, et al.
Pageof 22